Valuation dashboard for BriaCell Therapeutics Corp. (BCTX) with P/E N/A, P/B 1.06, EV/EBITDA -0.75 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $3.56, BCTX has negative trailing earnings (P/E not meaningful) and an ROE of -147.92%. Market capitalisation stands at $31M.
Balance sheet quality for BCTX: current ratio of 5.0. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 1.06 |
| EV / EBITDA | -0.75 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $4.23 |
| vs Current Price | +18.7% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| BCTX | BriaCell Therapeutics Corp. | $31M | 1.06 | -147.9% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $3.56 |
| Market Cap | $31M |
| Exchange | NASDAQ |
| Country | CA |
Profitability
| Return on Equity | -147.92% |
| Return on Invested Capital | -136.31% |
| Return on Assets | -113.23% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALLR · ASBP · CRIS · CTXR · ENTO · HOTH · LPTX
Explore sector: Healthcare · Biotechnology
More sections of BCTX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks